| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.2217/14622416.6.7.701 |
| P698 | PubMed publication ID | 16207147 |
| P2093 | author name string | Ioannis S Vizirianakis | |
| P2860 | cites work | A vision for the future of genomics research | Q22337251 |
| Genetic variations in HLA-B region and hypersensitivity reactions to abacavir | Q28214097 | ||
| Emerging clinical applications of RNA | Q28214164 | ||
| Systematic genome-wide screens of gene function | Q28237409 | ||
| Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies | Q29616299 | ||
| Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review | Q34102026 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug | Q34139151 | ||
| Inheritance and drug response | Q34175608 | ||
| Pharmacogenomics--drug disposition, drug targets, and side effects | Q34175616 | ||
| Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future | Q34310938 | ||
| Pharmacogenomics: the inherited basis for interindividual differences in drug response | Q34433440 | ||
| Genetic variations in human G protein-coupled receptors: implications for drug therapy | Q34461998 | ||
| Implications of cytochrome P450 interactions when prescribing medication for hypertension | Q34543308 | ||
| Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine | Q34581712 | ||
| Arylamine N-acetyltransferases and drug response | Q34673370 | ||
| Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity | Q34688246 | ||
| Encoding microcarriers: present and future technologies. | Q34742148 | ||
| Histone-deacetylase inhibitors: novel drugs for the treatment of cancer | Q34743301 | ||
| Advances in the development of genetic markers for the diagnosis of disease and drug response. | Q34884611 | ||
| Genetic polymorphisms of the human MDR1 drug transporter | Q34931160 | ||
| Pharmacogenomics: the future of drug therapy. | Q34952587 | ||
| Genomic medicine--a primer | Q34992066 | ||
| Pharmacogenomics of hypertension | Q35032370 | ||
| Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics | Q35043482 | ||
| Molecular diagnostics: a healthcare perspective | Q35045264 | ||
| Disruption of differentiation in human cancer: AML shows the way. | Q35058575 | ||
| Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease--pathophysiological considerations | Q35073288 | ||
| Peptide and protein drug delivery to and into tumors: challenges and solutions | Q35080230 | ||
| Lab-on-a-chip for drug development | Q35082120 | ||
| Pharmacogenomics: implications and considerations for pharmacists | Q35116109 | ||
| Pharmacogenomics of human UDP-glucuronosyltransferase enzymes | Q35157993 | ||
| Pharmacogenomic considerations in drug delivery | Q35164676 | ||
| Beyond Herceptin and Gleevec | Q35206946 | ||
| The application of functional genomics to Alzheimer's disease | Q35207554 | ||
| Pharmacogenetic considerations in diseases of cardiac ion channels | Q35560944 | ||
| Mechanisms involved in the induced differentiation of leukemia cells | Q35598922 | ||
| Cancer pharmacogenetics: polymorphisms, pathways and beyond | Q35636969 | ||
| Pharmacogenomics of proton pump inhibitors | Q35689146 | ||
| Pharmacogenetics in the treatment of breast cancer | Q35692680 | ||
| Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment | Q35699181 | ||
| Common gene polymorphisms, cancer progression and prognosis | Q35754435 | ||
| Improving the efficiency of RNA interference in mammals | Q35773259 | ||
| Molecular biomarkers in drug development | Q35946295 | ||
| Strategies to overcome resistance to targeted protein kinase inhibitors | Q35968384 | ||
| Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice | Q36320687 | ||
| Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine | Q40601170 | ||
| Exploiting human genetic variation in drug discovery and development | Q40727856 | ||
| Emerging developments in RNA therapeutics | Q44386192 | ||
| Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose | Q46433362 | ||
| Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. | Q47618340 | ||
| Pharmacogenetics in the laboratory and the clinic. | Q54269695 | ||
| Pharmacogenetic prediction of clozapine response | Q57403405 | ||
| Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter GeneABCB1 | Q57840857 | ||
| P433 | issue | 7 | |
| P921 | main subject | pharmacotherapy | Q701216 |
| pharmacogenomics | Q1152227 | ||
| P304 | page(s) | 701-711 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Pharmacogenomics | Q15724625 |
| P1476 | title | Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality? | |
| P478 | volume | 6 |
Search more.